OBJECTIVE: To evaluate the need for the BCG revaccination programme of schoolchildren in Finland. DESIGN: Investigating tuberculin sensitivity using the standard WHO Mantoux test and developing a model to estimate the risk of discontinuation, assuming that the annual incidence of tuberculosis within ten years after revaccination will remain at its present level; that the revaccination rate will be 2, 6 or 20%; and that the degree of protection will be 10, 20, 40 or 80%. SETTING AND PARTICIPANTS: Urban and rural schoolchildren--3,346 vaccinated with Copenhagen and 655 with Glaxo BCG vaccine at birth. RESULTS OF DATA ANALYSIS: The annual incidence of tuberculosis was 4.2 per 100,000 in the age-group 15-24 years. BCG revaccination was given formerly to 20% of the age cohort but nowadays only 6% or 2% meet the criteria after receiving either Copenhagen or Glaxo BCG at birth. After discontinuation the expected increase of tuberculosis in the age-group 15-24 years is predicted to fall within the limits of 0.1-24 cases per year. If 2% are left without revaccination the increase will be 0.1-2.4 cases. CONCLUSIONS: Due to the low annual incidence of tuberculosis in adolescents and to the small risk of increase the BCG revaccination programme has been discontinued from 1990 onwards.
OBJECTIVE: To evaluate the need for the BCG revaccination programme of schoolchildren in Finland. DESIGN: Investigating tuberculin sensitivity using the standard WHO Mantoux test and developing a model to estimate the risk of discontinuation, assuming that the annual incidence of tuberculosis within ten years after revaccination will remain at its present level; that the revaccination rate will be 2, 6 or 20%; and that the degree of protection will be 10, 20, 40 or 80%. SETTING AND PARTICIPANTS: Urban and rural schoolchildren--3,346 vaccinated with Copenhagen and 655 with Glaxo BCG vaccine at birth. RESULTS OF DATA ANALYSIS: The annual incidence of tuberculosis was 4.2 per 100,000 in the age-group 15-24 years. BCG revaccination was given formerly to 20% of the age cohort but nowadays only 6% or 2% meet the criteria after receiving either Copenhagen or Glaxo BCG at birth. After discontinuation the expected increase of tuberculosis in the age-group 15-24 years is predicted to fall within the limits of 0.1-24 cases per year. If 2% are left without revaccination the increase will be 0.1-2.4 cases. CONCLUSIONS: Due to the low annual incidence of tuberculosis in adolescents and to the small risk of increase the BCG revaccination programme has been discontinued from 1990 onwards.
Authors: Adam Edvin Roth; Christine Stabell Benn; Henrik Ravn; Amabelia Rodrigues; Ida Maria Lisse; Maria Yazdanbakhsh; Hilton Whittle; Peter Aaby Journal: BMJ Date: 2010-03-15
Authors: Helen A Fletcher; Rachel Tanner; Robert S Wallis; Joel Meyer; Zita-Rose Manjaly; Stephanie Harris; Iman Satti; Richard F Silver; Dan Hoft; Beate Kampmann; K Barry Walker; Hazel M Dockrell; Uli Fruth; Lew Barker; Michael J Brennan; Helen McShane Journal: Clin Vaccine Immunol Date: 2013-08-28
Authors: Joaquim C V D Van-Dunem; Laura C Rodrigues; Luiz Claudio Arraes Alencar; Maria de Fátima Pessoa Militão-Albuquerque; Ricardo Arraes de Alencar Ximenes Journal: Biomed Res Int Date: 2015-06-29 Impact factor: 3.411